share_log

Stifel Initiates Coverage On Neumora Therapeutics With Buy Rating, Announces Price Target of $26

Stifel Initiates Coverage On Neumora Therapeutics With Buy Rating, Announces Price Target of $26

Stifel以買入評級開始對Neumora Therapeutics進行報道,宣佈目標股價爲26美元
Benzinga ·  2023/10/10 05:47

Stifel analyst Paul Matteis initiates coverage on Neumora Therapeutics (NASDAQ:NMRA) with a Buy rating and announces Price Target of $26.

Stifel分析師Paul Matteis對Neumora Treeutics(納斯達克:NMRA)的報道給予買入評級,並宣佈目標價為26美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論